OHI Stock Analysis: Omega Healthcare Investors | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 14.439m USD | 12M Return: 16% | US6819361006 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 79.3M
EPS Trend: 94.9%
Qual. Beats: 1
Rev. Trend: 98.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Omega Healthcare Investors (NYSE: OHI) is a US-based real estate investment trust (REIT) that owns and leases healthcare properties, primarily skilled nursing facilities (SNFs) and assisted living facilities, to operating companies across the US, the UK, and Canada. The company employs a triple-net lease structure, meaning tenants are responsible for property taxes, insurance, and maintenance costs in addition to rent, which allows the REIT to collect relatively predictable rental income while limiting its own property-level operating expenses.
Incorporated in Maryland and headquartered in Hunt Valley, Maryland, OHI falls within the GICS Health Care REITs sub-industry and has been publicly traded since August 1992. As a REIT, it is generally required by US tax rules to distribute a substantial portion of its taxable income to shareholders in the form of dividends.
- SNF occupancy recovery lifts tenant rent coverage
- Medicaid reimbursement cuts pressure operator margins
- Rising rates pressure dividend yield versus bonds
| Net Income: 858.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.61 > 1.0 |
| NWC/Revenue: -2.53% < 20% (prev 219.5%; Δ -222.0% < -1%) |
| CFO/TA 0.09 > 3% & CFO 890.6m > Net Income 858.3m |
| Net Debt (3.98b) to EBITDA (1.45b): 2.75 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (316.2m) vs 12m ago 4.29% < -2% |
| Gross Margin: 71.96% > 18% (prev 98.78%; Δ -26.82% > 0.5%) |
| Asset Turnover: 12.55% > 50% (prev 10.57%; Δ 1.98% > 0%) |
| Interest Coverage Ratio: 5.38 > 6 (EBIT TTM 1.12b / Interest Expense TTM 207.8m) |
| A: -0.00 (Total Current Assets 315.1m - Total Current Liabilities 347.9m) / Total Assets 10.0b |
| B: -0.35 (Retained Earnings -3.51b / Total Assets 10.0b) |
| C: 0.11 (EBIT TTM 1.12b / Avg Total Assets 10.3b) |
| D: 1.23 (Book Value of Equity 5.39b / Total Liabilities 4.37b) |
| Altman-Z'' = 0.86 = B |
| DSRI: 0.12 (Receivables 276.1m/2.02b, Revenue 1.29b/1.11b) |
| GMI: 1.37 (GM 98.78% / 71.96%) |
| AQI: 3.35 (AQ_t 0.30 / AQ_t-1 0.09) |
| SGI: 1.16 (Revenue 1.29b / 1.11b) |
| TATA: -0.00 (NI 858.3m - CFO 890.6m) / TA 10.0b) |
| Beneish M = -1.91 (Cap -4..+1) = B |
As of October 20, 2026, the stock is trading at USD 44.89 with a total of 1,315,499 shares traded. Over the past week, the price has changed by -0.62%, over one month by -4.14%, over three months by -8.23% and over the past year by +15.98%.
Current recommended Stop Loss: 43.70 (which is 2.7% or 1.4 ATR below the current price).
Omega Healthcare Investors has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold OHI.
- StrongBuy: 6
- Buy: 2
- Hold: 10
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 51.4 | 14.6% |
P/E Trailing = 16.15
P/E Forward = 10.1317
P/S = 11.4468
P/B = 2.5953
P/EG = 11.994
Revenue TTM = 1.29b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 4.02b USD (from longTermDebt, last quarter)
Short Term Debt = 6.00m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.98b USD (calculated: Debt 4.02b - CCE 39.0m)
Enterprise Value = 18.4b USD (14.4b + Debt 4.02b - CCE 39.0m)
Interest Coverage Ratio = 5.38 (Ebit TTM 1.12b / Interest Expense TTM 207.8m)
EV/FCF = 20.39x (Enterprise Value 18.4b / FCF TTM 903.3m)
FCF Yield = 4.90% (FCF TTM 903.3m / Enterprise Value 18.4b)
FCF Margin = 69.92% (FCF TTM 903.3m / Revenue TTM 1.29b)
Net Margin = 66.43% (Net Income TTM 858.3m / Revenue TTM 1.29b)
Gross Margin = 71.96% ((Revenue TTM 1.29b - Cost of Revenue TTM 362.3m) / Revenue TTM)
Gross Margin QoQ = 46.41% (prev none%)
Tobins Q-Ratio = 1.83 (Enterprise Value 18.4b / Total Assets 10.0b)
Interest Expense / Debt = 5.17% (Interest Expense 207.8m / Debt 4.02b)
Taxrate = 1.79% (16.3m / 911.5m)
NOPAT = 1.10b (EBIT 1.12b * (1 - 1.79%))
Current Ratio = 0.91 (Total Current Assets 315.1m / Total Current Liabilities 347.9m)
Debt / Equity = 0.75 (Debt 4.02b / totalStockholderEquity, last quarter 5.39b)
Debt / EBITDA = 2.75 (Net Debt 3.98b / EBITDA 1.45b)
Debt / FCF = 4.41 (Net Debt 3.98b / FCF TTM 903.3m)
Total Stockholder Equity = 5.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.34% (Net Income 858.3m / Total Assets 10.0b)
RoE = 16.51% (Net Income TTM 858.3m / Total Stockholder Equity 5.20b)
RoCE = 12.12% (EBIT 1.12b / Capital Employed (Equity 5.20b + L.T.Debt 4.02b))
RoIC = 11.36% (NOPAT 1.10b / Invested Capital 9.66b)
WACC = 4.87% (E(14.4b)/V(18.5b) * Re(4.81%) + D(4.02b)/V(18.5b) * Rd(5.17%) * (1-Tc(0.02)))
Discount Rate = 4.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.89 | Cagr: 9.61%
[DCF] Terminal Value 77.97% ; FCFF base≈853.8m ; Y1≈978.8m ; Y5≈1.44b
[DCF] Fair Price = 58.41 (EV 21.7b - Net Debt 3.98b = Equity 17.7b / Shares 303.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.93 | EPS CAGR: 21.69% | SUE: 0.90 | # QB: 1
Revenue Correlation: 98.91 | Revenue CAGR: 14.18% | SUE: 0.80 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=+3.89% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=1.98 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-2.7% | GrowthRev=+9.9%
EPS next Year (2027-12-31): EPS=2.02 | Chg30d=-1.05% | Revisions=+0% | GrowthEPS=+2.2% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -17% (up=1, down=2)